This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Caprini, J. A. Articles by Hathaway, K. Search for Related Content PubMed PubMed Citation Articles by Caprini, J. A. Articles by Hathaway, K. Pubmed/NCBI databases Substance via MeSH

(Circulation. 2004;109:I-4 – I-8.)
© 2004 American Heart Association, Inc.

Diagnosis of Venous Thromboembolism

Laboratory Markers in the Diagnosis of Venous Thromboembolism

Joseph A. Caprini, MD; Catherine J. Glase, BS; Christopher B. Anderson, BS; Karen Hathaway, BS

From the Department of Surgery, Evanston Northwestern Healthcare (J.A.C., C.J.G., C.B.A., K.H.), Evanston, Ill; and Northwestern University Feinberg School of Medicine (J.A.C.), Chicago, Ill.

Correspondence to Joseph A. Caprini, MD, FACS, Evanston Northwestern Healthcare, Burch 104, 2650 Ridge Ave, Evanston, IL 60201. E-mail j-caprini{at}northwestern.edu

Abstract

Selected blood tests may be useful in the diagnosis of venous thromboembolism (VTE), or in the identification of a congenital or acquired defect associated with the development of VTE. Several studies have shown the D-dimer assay to have a high negative predictive value but poor specificity when used in the detection of VTE. Yet in the emergency room setting, the D-dimer test may be useful if a detailed risk factor analysis for each patient is included in the diagnosis. The presence of such genetic thrombophilia markers as factor V Leiden, prothrombin 20210A mutation, and antiphospholipid antibodies significantly increases a patient’s risk of a thrombotic event. The relative risk of thrombosis in factor V heterozygotes is at least 3 times higher than in the general population, whereas the increased risk of thrombosis in homozygotes is estimated to be 50- to 80-fold greater than those without the defect. Thromboembolic events are reported in approximately one third of antiphospholipid-positive patients. Other markers such as hyperhomocysteinemia and deficiencies of antithrombin, protein C, or protein S, when combined with the previous mutations, significantly increase a patient’s risk of a thrombotic event. We feel that it is important to identify these ultra-high-risk patients to provide adequate counseling about the risk of thrombosis before elective surgical procedures. Often, lifelong anticoagulation may be needed as these patients and family members may need testing before taking birth control pills or hormonal replacement.

Key Words: thrombosis • genetics • diagnosis